GoAI
Get started
Nanjing Sinolife United Company Limited logo

Nanjing Sinolife United Company Limited

3332.HK

HKSEHealthcareMedical - Pharmaceuticals

Open in GoAI

Latest quote

HK$0.149

−HK$0.014 · -8.59%

Aug 24, 3:28 PM HKT

3332.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Nanjing Sinolife United Company Limited functions as an investment holding entity primarily involved in the manufacturing, processing, and global distribution of nutritional supplements. Its operations span the People's Republic of China, Australia, New Zealand, Vietnam, and various international markets. The firm additionally produces and markets cosmetics and skincare items, while also undertaking the trading, retail, and testing of pre-packaged health food products. Products are sold under well-known brands such as Good Health, Zhongsheng, Hejian, and Cobayer, primarily via its comprehensive network of retail outlets. Distribution also encompasses sales through distributors, television shopping channels, online e-commerce platforms, chain pharmacies, specialized health food supermarkets, and tourist souvenir shops. The company, which has been headquartered in Nanjing, China, since its establishment in 1999.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
Headquarters
CN
CEO
Yuan Zhang
Listed since
Jan 15, 2014
Employees
519

Market position

Day range

Current HK$0.149

52-week range

Current HK$0.149

Open
HK$0.163
Previous close
HK$0.163
Volume
300K
1.38× average
Average volume
216.89K
Average daily volume
Market cap
141M HKD
Beta
-0.12
Market reference 1
50-day average
HK$0.1517
-1.75% below average
200-day average
HK$0.3018
-50.63% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
189.88M CNY
P/E (TTM)
4.89×
P/B (TTM)
0.29×
P/S (TTM)
0.16×
EV / EBITDA
5.98×
Earnings yield
7.64%
Free cash flow yield
20.10%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
73.25%
Operating margin
2.97%
Net margin
3.19%
Return on equity
5.91%
Return on assets
4.09%
Return on invested capital
3.95%

Financial health

Debt / equity
0.26×
Current ratio
2.68×
Altman Z-score
3.13
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends82%48%13%-21%Gross margin, FY2021: 55.01%Gross margin, FY2022: 58.21%Gross margin, FY2023: 67.32%Gross margin, FY2024: 71.97%Gross margin, FY2025: 73.25%Operating margin, FY2021: -12.50%Operating margin, FY2022: -4.86%Operating margin, FY2023: 10.04%Operating margin, FY2024: 5.36%Operating margin, FY2025: 2.97%Net margin, FY2021: -12.57%Net margin, FY2022: -5.18%Net margin, FY2023: 9.33%Net margin, FY2024: 4.62%Net margin, FY2025: 3.19%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 55.01%. Gross margin FY2022 58.21%. Gross margin FY2023 67.32%. Gross margin FY2024 71.97%. Gross margin FY2025 73.25%. Operating margin FY2021 -12.50%. Operating margin FY2022 -4.86%. Operating margin FY2023 10.04%. Operating margin FY2024 5.36%. Operating margin FY2025 2.97%. Net margin FY2021 -12.57%. Net margin FY2022 -5.18%. Net margin FY2023 9.33%. Net margin FY2024 4.62%. Net margin FY2025 3.19%.

Income trends

Revenue

772.93M CNY+3.35%

Operating income

22.98M CNY-42.72%

Net income

24.67M CNY-28.64%
Income trends across reported periods853.39M CNY531.54M CNY209.68M CNY−112.17M CNYRevenue, FY2021: 252.33M CNYRevenue, FY2022: 274.85M CNYRevenue, FY2023: 563.96M CNYRevenue, FY2024: 747.9M CNYRevenue, FY2025: 772.93M CNYOperating income, FY2021: −31.53M CNYOperating income, FY2022: −13.37M CNYOperating income, FY2023: 56.61M CNYOperating income, FY2024: 40.12M CNYOperating income, FY2025: 22.98M CNYNet income, FY2021: −31.71M CNYNet income, FY2022: −14.25M CNYNet income, FY2023: 52.6M CNYNet income, FY2024: 34.56M CNYNet income, FY2025: 24.67M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 252.33M CNY. Revenue FY2022 274.85M CNY. Revenue FY2023 563.96M CNY. Revenue FY2024 747.9M CNY. Revenue FY2025 772.93M CNY. Operating income FY2021 −31.53M CNY. Operating income FY2022 −13.37M CNY. Operating income FY2023 56.61M CNY. Operating income FY2024 40.12M CNY. Operating income FY2025 22.98M CNY. Net income FY2021 −31.71M CNY. Net income FY2022 −14.25M CNY. Net income FY2023 52.6M CNY. Net income FY2024 34.56M CNY. Net income FY2025 24.67M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue772.93M CNY747.9M CNY563.96M CNY274.85M CNY252.33M CNY
Cost of goods sold206.74M CNY209.63M CNY184.3M CNY114.86M CNY113.52M CNY
Gross profit566.19M CNY538.27M CNY379.66M CNY160M CNY138.8M CNY
Research and development1.32M CNY924K CNY867K CNY836K CNY1.29M CNY
Selling, general, and administrative541.88M CNY497.22M CNY322.18M CNY172.53M CNY176.2M CNY
Operating expenses543.2M CNY498.15M CNY323.05M CNY172.09M CNY177.49M CNY
Interest income2.9M CNY1.37M CNY852K CNY329K CNY357K CNY
Interest expense3.72M CNY3.39M CNY3.28M CNY472K CNY685K CNY
Depreciation and amortization9.53M CNY10.65M CNY13.71M CNY14.91M CNY18.93M CNY
Operating income22.98M CNY40.12M CNY56.61M CNY−13.37M CNY−31.53M CNY
Net income24.67M CNY34.56M CNY52.6M CNY−14.25M CNY−31.71M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
0

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.080.03-0.02-0.07Q2 '21Q4 '21Q3 '22Q2 '23Q3 '23Q1 '24Q3 '24Q1 '25
Q2 2021, reported Jun 30, 2021: actual -0.009, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual -0.032, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 30, 2022: actual -0.006, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Apr 21, 2023: actual -0.011, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 24, 2023: actual 0.032, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 27, 2024: actual 0.029, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 24, 2024: actual 0.038, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 26, 2025: actual 0.001, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates654.86M477.29M299.72M122.15MQ2 '21No estimateQ4 '21No estimateQ3 '22MissQ2 '23MissQ3 '23MissQ1 '24MissQ3 '24No estimateQ1 '25No estimate
Q2 2021, reported Jun 30, 2021: actual 148.53M HKD, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual 157.47M HKD, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 30, 2022: actual 143.71M HKD, estimate 617M HKD, surprise -76.71%, Miss. Q2 2023, reported Apr 21, 2023: actual 173.22M HKD, estimate 617M HKD, surprise -71.93%, Miss. Q3 2023, reported Aug 24, 2023: actual 236.76M HKD, estimate 617M HKD, surprise -61.63%, Miss. Q1 2024, reported Mar 27, 2024: actual 381.88M HKD, estimate 617M HKD, surprise -38.11%, Miss. Q3 2024, reported Aug 24, 2024: actual 397.55M HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 26, 2025: actual 401.81M HKD, estimate —, surprise —, Comparison unavailable.

3332.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.7

-3.94%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.46

-3.61%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.50

-2.83%

Continue in GoAI

Research 3332.HK

research.disclaimer